 |
Jerusalem, Israel, December 17, 2001
Teva Announces Final Approval of Lovastatin Tablets
|
|
Jerusalem, Israel, December 4, 2001
Teva and Proneuron Biotechnologies Entered into an Agreement to Develop glatiramer acetate for Multiple Neurodegenerative Diseases
|
|
Jerusalem, Israel, November 14, 2001
Teva not Acquiring Faulding Injectable Business
|
|
Jerusalem, Israel, October 23, 2001
Teva to Announce Third Quarter Earnings
|
|
Jerusalem, Israel, October 10, 2001
Teva Announces that Health Canada Has Approved Enhanced Labeling for Copaxone®
|
|
KANSAS City, Mo. and Jerusalem, Israel, October 1, 2001
Teva's Copaxone® Shown to Reduce "Black Holes" in the Brain
|
|
Jerusalem, Israel, September 19, 2001
Teva Announces Approval of Enalapril / HCTZ Tablets
|
|
Jerusalem, Israel, September 19, 2001
Teva Announces Approval of Flutamide Capsules
|
|
Jerusalem, September 14, 2001
Teva Pharmaceutical Industries Announce Interim Results of Coral Study
|
|
Jerusalem, Israel, August 15, 2001
Teva to Hold Conference Call on Wednesday, August 15, 2001
|
|
Jerusalem, Israel, August 15, 2001
Teva Announces Pricing Of $300 Million Convertible Debenture Offering
|
|
Jerusalem, Israel, August 14, 2001
Teva Wins Nabumetone Lawsuit Will Commence Sales of Generic Equivalent of Relafen® Immediately
|
|
Jerusalem, Israel, August 14, 2001
Teva Announces Offering of Convertible Debentures in a Rule 144a Offering
|
|
Jerusalem, Israel, August 13, 2001
Teva’s Board Declared a Cash Dividend for Q2 2001 of Approx. 6.5¢
|
|
Jerusalem, Israel, August 9, 2001
Teva Announces Tentative Approval of Buspirone HCI Tablets, 15mg
|
|
Jerusalem, Israel, August 7, 2001
15 European Countries Agree to Approve Copaxone®
|
|
Jerusalem, Israel, August 2, 2001
Teva Announces Final Approval of Fluoxetine Oral Solution
|
|
Jerusalem, Israel, July 25, 2001
Teva Reports a 41% Increase in Second Quarter Net Income on an Increase in Sales of 16% EPS Reached $0.47, Up 38%
|
|
Jerusalem, Israel, July 16, 2001
Teva to Announce Second Quarter Earnings
|
|
Jerusalem, Israel, July 12, 2001
Conference Call: Teva Announces Cooperation with Mayne Nickless
|
|
Jerusalem, Israel, July 12, 2001
Teva Announces Cooperation with Mayne Nickless in Bid for F.H. Faulding & Co. Ltd
|
|
Hayward ,Calif. and Jerusalem, Israel, June 27, 2001
Impax and Teva Announce Strategic Alliance for Generic Controlled Release Products
|
|
Jerusalem, Israel, June 17, 2001
Teva Announces Approval of Lovastatin Tablets
|
|
Jerusalem, Israel, June 3, 2001
Teva Announces Tentative Approval for Fluoxetine 10mg
|
|
Jerusalem, Israel, May 31, 2001
Teva Announces Final Approval of Famotidine Tablets,10mg
|
|
Jerusalem, Israel, May 2, 2001
Teva Reports First Quarter 2001 Results Sales Up 46%; Net Income Up 56%; EPS Up 43%
|
|
Jerusalem, Israel, April 18, 2001
Teva Announces First Quarter Earnings Conference Call
|
|
Jerusalem, Israel, April 17, 2001
Teva Announces Final Approval of Famotidine 20 & 40mg
|
|
Jerusalem, Israel, February 15, 2001
Teva Reports Record Fourth Quarter and Year 2000 Results Earnings Per ADR: $0.43
|
|
Jerusalem, Israel, February 14, 2001
Teva Concludes Strategic Agreements with Aventis to Acquire TMP, and with Lundbeck to Extend the Existing Cooperation to Oral Copaxone®
|
|
Jerusalem, Israel, February 11, 2001
Teva Announces Fourth Quarter Earnings Conference Call
|
|
Jerusalem, Israel, February 7, 2001
Teva Announces Final Approvals of Nifedipine XL 30mg and Etodolac ER 400mg
|
|
Jerusalem, Israel, January 2, 2001
Teva Reaffirms Confidence in Sales of Sustained Release Generic Products
|
